Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure.
Luraghi A, Ferrandi M, Barassi P, Arici M, Hsu SC, Torre E, Ronchi C, Romerio A, Chang GJ, Ferrari P, Bianchi G, Zaza A, Rocchetti M, Peri F.
Luraghi A, et al. Among authors: zaza a.
J Med Chem. 2022 May 26;65(10):7324-7333. doi: 10.1021/acs.jmedchem.2c00347. Epub 2022 May 17.
J Med Chem. 2022.
PMID: 35580334
Free PMC article.